Alps Advisors Inc I Mab Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.18 - $3.06 $1,100 - $2,854	-933 Reduced 1.52%	60,400 $79,000
Q2 2023 Aug 14, 2023	BUY	$2.95 - $3.85 $19,644 - $25,637	6,659 Added 12.18%	61,333 $183,000
Q1 2023 May 10, 2023	SELL	$3.08 - $7.39 $5,433 - $13,035	-1,764 Reduced 3.13%	54,674 $189,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $36,389 - $54,922	11,301 Added 25.04%	56,438 $235,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $15,590 - $47,977	-3,888 Reduced 7.93%	45,137 $181,000

Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $405,436 - $903,530	49,025 New	49,025 $554,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.